Management of Hyperlipidemia After Stroke

被引：12
作者：
Brooks, Daniel C. [1 ,2 ]
Schindler, Joseph L. [3 ]
机构：
[1] Stamford Hlth Med Grp, Dept Internal Med, Div Neurol, Stamford, CT USA
[2] Stamford Hosp, Stamford, CT USA
[3] Yale Univ, Sch Med, Dept Neurol, POB 208018, New Haven, CT 06520 USA
来源：
CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE | 2019年 / 21卷 / 12期
关键词：
Stroke; TIA; ICH; LDL-C; Hyperlipidemia; Dyslipidemia;
D O I：
10.1007/s11936-019-0774-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Purpose of review Hyperlipidemia is a key therapeutic target for stroke risk modification. The goal of this review is to highlight available treatment options and review their efficacy in the setting of general cardiovascular disease and after most subtypes of ischemic stroke and hemorrhagic stroke. Recent findings Statins remain first-line in the management of hyperlipidemia to prevent stroke. In recent trials of patients with pre-existing atherosclerotic vascular disease, new agents, most notably PCSK9 inhibitors and ezetimibe, added additional stroke risk reduction when combined with statins. Risk of stroke can be significantly reduced by understanding that hyperlipidemia is a key therapeutic target, particularly in patients with cardiovascular disease, and by identifying patients who may benefit from aggressive LDL-C reduction with statins +/- novel agents.
引用
收藏
页数：15
相关论文
共 89 条
[81]  
Poon M.T., Fonville A.F., Al-Shahi Salman R., Long-term prognosis after intracerebral hemorrhage: systematic review and meta-analysis, J Neurol Neurosurg Psychiatry, 85, 6, pp. 660-667, (2014)
[82]  
Hanger H.C., Et al., The risk of recurrent stroke after intracerebral hemorrhage, J Neurol Neurosurg Psychiatry, 78, 8, pp. 836-840, (2007)
[83]  
Cheung B.M.Y., Lam K.S.L., Never too old for statin treatment?, Lancet, 393, 10170, pp. 379-380, (2019)
[84]  
Gurwitz J.H., Go A.S., Fortmann S.P., Statins for primary prevention in older adults: uncertainty and the need for more evidence, JAMA, 316, 19, pp. 1971-1972, (2016)
[85]  
Sturgeon J.D., Et al., Risk factors for intracerebral hemorrhage in a pooled prospective study, Stroke, 38, 10, pp. 2718-2725, (2007)
[86]  
Ma C., Et al., Low-Density Lipoprotein Cholesterol and Risk of Intracerebral Hemorrhage: A Prospective Study, (2019)
[87]  
Saliba W., Rennert H.S., Barnett-Griness O., Gronich N., Molad J., Rennert G., Auriel E., Association of statin use with spontaneous intracerebral hemorrhage, Neurology, 91, 5, pp. e400-e409, (2018)
[88]  
Collins R., Et al., Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions, Lancet, 363, 9411, pp. 757-767, (2004)
[89]  
Matthews A., Et al., Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data, BMJ, 353, (2016)
123456789